Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Beigene Tislelizumab , Shachar Shlosberger , Enlivex Therapeutics Ltd , Hc Wainwright Co , Bristol Myers Squibb , Nasdaq , Beigene Ltd , Wall Street , Enlivex Therapeutics , Therapeutics Ltd , Nektar Therapeutic ,